---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059130"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:31:28.517144+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics Q1 net loss $19.0M; cash $56.5M; lead candidate CT-0525 prioritized

## Summary
- Net loss $19.0M for Q1 2024 vs $24.6M in Q1 2023; R&D expenses $17.5M.
- Cash $56.5M as of March 31, 2024; expected to fund operations into Q3 2025.
- Pipeline reprioritization: CT-0525 becomes lead; CT-0508 enrollment ceased; CT-1119 paused; workforce reduced ~37%.
- Initial CT-0525 Phase 1 data expected by year-end 2024; preclinical fibrosis data presented at ASGCT.
- Appointed Eugene Kennedy as CMO; John Hohneker to Board; Chidozie Ugwumba resigned.

## SEC filing metadata
- accession: 0001104659-24-059130
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/0001104659-24-059130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/tm2413903d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059130
- JSON: https://secwatch.observer/filing/0001104659-24-059130.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059130.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/0001104659-24-059130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.